94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1453344
This article is part of the Research Topic Community Series in Methods in Cancer Immunity and Immunotherapy: Volume II View all 5 articles
Research progress of T cells in cholangiocarcinoma
Provisionally accepted
Zhiming Wang 1
Yunyan Dai 1
Yunpeng Zhou 1
Yi Wang 1
Pinggui Chen 1
Yaoxuan Li 1 Yunfei Zhang 2 Xiaocui Wang 2 Ying Hu 2 Haonan Li 2
Gaopeng Li 1*
Yukai Jing 2*- 1 Department of General Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, China
- 2 Department of Clinical Laboratory, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, China
Cholangiocarcinoma (CCA), a malignant tumor, is typically challenging to detect early and often results in a poor prognosis. In recent years, research interest has grown in the potential application of immunotherapy for CCA treatment. T cells, as a crucial component of the immune system, play a significant role in immune surveillance and therapy for cholangiocarcinoma. This article provides a review of the research advancements concerning T cells in cholangiocarcinoma patients, including their distribution, functional status, and correlation with patient prognosis within the tumor microenvironment. It further discusses the potential applications and challenges of immunotherapy strategies targeting T cells in CCA treatment and anticipates future research directions. A more profound understanding of T cells' role in cholangiocarcinoma can guide the development of clinical treatment strategies, thereby enhancing patient survival rates and quality of life. Finally, we explored the potential risks and side effects of immunotherapy for T-cell cholangiocarcinoma
Keywords: Cholangiocarcinoma, T lymphocytes, Tumor Microenvironment, Immunotherapy, Immunization checkpoints
Received: 23 Jun 2024; Accepted: 06 Feb 2025.
Copyright: © 2025 Wang, Dai, Zhou, Wang, Chen, Li, Zhang, Wang, Hu, Li, Li and Jing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Gaopeng Li, Department of General Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, China
Yukai Jing, Department of Clinical Laboratory, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, 030032, Shanxi Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.